Chemo plus immunotherapy for HR+/HER2- breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 75
- Breast cancer that is HR-positive and HER2-negative, with a tumor larger than 1 cm
- Breast cancer has not spread to distant organs (Stage I to III)
- Good overall health (able to do daily activities without help)
- Normal blood counts and kidney/liver function
- Willing to use effective birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests a combination of chemotherapy, an immunotherapy drug, and two different schedules of radiation before surgery for a common type of breast cancer. The goal is to find which radiation approach works better and to improve outcomes.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.